NCT03517540: A reported trial by Novartis Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03517540 |
|---|---|
| Title | A Randomized, Double-blind, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 11, 2018 |
| Completion date | Sept. 15, 2020 |
| Required reporting date | Sept. 15, 2023, midnight |
| Actual reporting date | Oct. 14, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |